6 independently sourced, verified trend briefs about this subject.
Newsylist includes a story here only after at least four independent sources support it and its brief passes the verification check. The qualifying coverage spans 2 news categories, from Jul 7, 2026 through Jul 25, 2026.
The cards below are ordered newest first. Each opens the underlying timeline, source list, coverage velocity and verification context; raw or extractive-only records are excluded.
Regulators and health advisors are warning of a rare but severe risk of vision loss associated with GLP-1 weight-loss medications.
A new economic study suggests a correlation between the use of GLP-1 weight-loss drugs and a 17% reduction in employee sick leave.
Novo Nordisk has filed a lawsuit against Eli Lilly, alleging the company used deceptive and false advertising regarding GLP-1 weight-loss medications.
New evidence suggests GLP-1 medications, including Ozempic and Wegovy, may serve as a promising treatment for binge eating disorder.
Recent studies examine the long-term impact of discontinuing GLP-1 weight-loss medications like Ozempic and Wegovy.
The Wegovy weight loss pill has launched in the UK, marking the arrival of the first daily oral GLP-1 medication for weight management.